Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.

The stock options have a ten-year term, and the exercise price is $30.40 per share, which is equal to the closing price of Vor Bio’s common stock on the grant date of the stock options and RSUs. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

VOR pivoted from cell therapy to in-licensing telitacicept, securing $175M in private placement but at the cost of massive dilution. Telitacicept offers multi-billion market potential if global trials ...

The average one-year price target for Vor Biopharma (NasdaqGS:VOR) has been revised to $36.46 / share. This is an increase of ...

Shares of Vor Bio VOR have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based ...

H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR), highlighting the company’s “rebirth” following the in-licensing of telitacicept. On Thursday, the company announced a strategic licensing ...

What are the strange white cone structures located in fields and what do they have to do with aviation? Although they’ve been around since the 1930s and widely in use since the 1970s, Very High ...